Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many patients with (a) blood cancer and (b) multiple myeloma have had their treatment switched from intravenous to oral treatment during the covid-19 outbreak; and what assessment he has made of the potential long term effect on patients of switching treatment regimens.

As at 23 June 2020, 230 patients with myeloma, 32 patients with mantle cell lymphoma, and 28 patients with acute myeloid leukaemia have had applications for treatment with oral therapies approved. These applications were all supported by clinicians.

The outcomes related to these new options can only be assessed in the long term and some audits of these patients are already underway.